NEW YORK, April 30, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Atlas Financial Holdings, Inc. (“Atlas” or the “Company”) (NASDAQ:AFH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Atlas securities between March 13, 2017, and March 2, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/afh.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) that the Company failed to employ internal controls to ensure appropriate accounting practices; including, but not limited to, the calculation of certain loss reserves; (2) that, as a result, the Company’s internal controls over financial reporting were materially weak; (3) that as a result the Company’s financial statements were inaccurate and misleading, including by understating certain loss reserves; and, (4) that, as a result of the foregoing, Defendants’ statements about Atlas Financial’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On March 2, 2018, Atlas announced it took a significant loss-reserve charge in the fourth quarter related to the Company’s commercial auto claims from 2015 and prior. On this news, the Company’s share price fell $7.70 or 40.96%, to close at $11.10 on March 2, 2018.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/afh or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Atlas you have until May 4, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market
YouTube Outage Disrupts Thousands Worldwide as Recommendation System Fails
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 



